‘Regular Order’ Restored For Legislation To Make Cannabinoids Lawful Under FDA Regulations
Executive Summary
De-scheduling provision in 2018 farm bill wasn’t crafted by House and Senate committees with FDA oversight, making it important that legislation to make hemp-derived cannabinoids lawful for use in supplements comes through House Energy and Commerce or Senate HELP committee.
You may also be interested in...
CBD Regulation Bill Filed In US House Again; VMS In Pre-Tax Savings Accounts In First Senate Vote
Hemp-Derived CBD bill either provides exact solution US needs for lawful use of cannabinoids as dietary ingredients or falls well short, depending on the trade group. Legislation to expand health savings accounts to include vitamin, mineral and supplement products reached Senate floor vote before failing.
Biden Administration Pause On Pending Trump-Era Rules Stalls FDA Cannabinoids Guidance Progress
Among four FDA regulatory items withdrawn from OMB review is “Cannabidiol Enforcement Policy; Draft Guidance for Industry,” which the agency submitted in July 2020.
No End To US FDA Concerns About DEG And EG Testing, Or To OTC Firms Not Answering Its Calls
One of firms targeted in eight most recent warnings published since early September to OTC drug manufacturers, Zhao Qing Longda Biotechnology Co. in China, was dinged for both failing to respond to a request for records and for concerns about its production with DEG and EG.